CDMO business optimisation through the absorption-type merger of スペラファーマ and 岩城製薬佐倉工場
An individual organisational restructuring in 2025 in which スペラファーマ absorbed 岩城製薬佐倉工場 through an absorption-type merger to optimise the overall CDMO business in the fine chemicals sector.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.